{"name":"Nuvectis Pharma","slug":"nuvectis","ticker":"NVCT","exchange":"NASDAQ","domain":"nuvectispharma.com","description":"Nuvectis Pharma is a precision oncology company focused on developing innovative treatments for cancer patients. The company's pipeline includes several promising candidates, including NV-513, a novel small molecule inhibitor. With a strong focus on precision medicine, Nuvectis aims to improve patient outcomes and quality of life. As a relatively new player in the oncology space, Nuvectis has significant growth potential.","hq":"Fort Lee, NJ","founded":2017,"employees":"~350","ceo":"Ron Bentsur","sector":"Precision Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"1.2B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":18153000,"netIncome":-26442000,"cash":31709000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"NV-513 patent cliff ($X.XB at risk)","drug":"NV-513","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Nuvectis Pharma Receives FDA Orphan Drug Designation for NV-513","summary":"Nuvectis Pharma announced that the FDA has granted Orphan Drug Designation to NV-513 for the treatment of a specific type of cancer.","drugName":"NV-513","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Nuvectis Pharma Reports Third Quarter 2023 Financial Results","summary":"Nuvectis Pharma reported its third quarter 2023 financial results, with revenue of $X.X million and a net loss of $Y.Y million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQYXdneUlYRHZ1M0U2NzVVcjgwUzFncWduWUk5U2c5dW44UUdtTXF5eU9TZzFlTjNDanpZTzQxWS01VUpZUElQT3JYWmN6ZFlPQVowcVhvQ2FLbG4wOHBuRjFDSmZfdW50eW5LeFB2My1BdS1YUTZCWTY0RXdiNVNYSkNzNnJLWmxKSllwREo3dzJtLXFSQl9PcFpRLTM0eGJfVG1uOG1oM292RzJNLXViNGJJbU8xV28?oc=5","date":"2026-04-02","type":"pipeline","source":"MarketBeat","summary":"Nuvectis Pharma (NASDAQ:NVCT) Trading Down 1.7% - Here's What Happened - MarketBeat","headline":"Nuvectis Pharma (NASDAQ:NVCT) Trading Down 1.7% - Here's What Happened","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE52cHhmNFFZX1NYUG5qUncxbUVYN3g0RU5wTFQ4ams0VXZUcHZtLXdKaG5JWWVVMVZCY1dQZklNVm11TnNPeFBweFZ2dDdNWEdPMzhRNHIzTy0tWGFieExJ?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"NVCT Stock Price, Quote & Chart | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill","headline":"NVCT Stock Price, Quote & Chart | NUVECTIS PHARMA INC (NASDAQ:NVCT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPVmN5NVpxWkMyMnRUQV96bF82VDJicXlHVEJISHZLVVVNZ3VfYTdvaERwdHZSN05sWG1xLXRDYy1WQ190TXdYWkxEMUZXNEtWNTRYY3VwYmN5bEVGWUdmc0NmcDV6RFhnWXdWOXBkUFU1SWpxTEtyekhDX1lHTUdFUXBqa05kZmJmRmhmVTMwTUN5eTVyVm9adC1VdDdNY2VCVUIyenFFb21rbVJGV1FCcl9YaHhZNkl0MXlRbFpiSFNwWDZwMmJRUU82MnhEbjNMQURUbU9OQ0tISWxxdVJoOQ?oc=5","date":"2026-04-01","type":"pipeline","source":"investingnews.com","summary":"Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting - investingnews.com","headline":"Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxQWGs1c01INVdBRlhPT1Rub2pYMDZBczlDM0JMSzBMZTQxdE5UX2dsTW1uTE9fd1R5WTZIb2stLXZMenhqX1JhQ3hqOHc1VDhyNnZYZllmdzVjTjJnMGw2eDk1SndQaGFLVXhvLV8zaVM5UHpTU3NJX3V6bHA1SXVxNFd3UnQ4QVQ4VmRndGhMZFMwMXBCUkpNV1JRR3czdkFmVEk4RnA2Y1ROUlFzZnpJMG8zQ0YyLXl2NFFhZlRweC1fQWZCRjNvOVBUNWNoZ2VONnFTRVNxSHEweHhGZXhzaExsODhqZE1rU1RvSGh1R3d0SERBbzdFQ0hNVHhiY1ByZXBlWDNxRQ?oc=5","date":"2026-03-31","type":"pipeline","source":"ChartMill","summary":"Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting - ChartMill","headline":"Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOTVlVdkxwYWtVeEN6VFN1WHI3NnRsaUE2Uzl0ZlVaN2NJOGZST2FjeTZFcC00Ty04NF8yeEV6TlFxNXRWRlQzcXV2MFdFNzdhSjlZWlBrNHdZV2tJYVdHOWl6NHdhV0NXUXU2M1RORnBRZ040VjNQMDN4U3NsLXFVWVZZUk9oNm1ET0VIMnNka0E?oc=5","date":"2026-03-24","type":"pipeline","source":"Yahoo Finance","summary":"Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation - Yahoo Finance","headline":"Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxPQjhjWkRiWThUNG96STFYTkExaEVMWjhQUGlpMzNVZlQ2REd3bFpOdUh1VU5VWFJQemVJX1VfQjVkQkZDazNnSmN5Q2tKWDh5VGN5WGtMSGMxd1JiTWVSVW5EbllJS1VIdVM3dWl2UVhVWlg3TGl0b28xVFNWcEFDX29USHNfaTk4ZWd0YUpxcGkwa043ZjVtUEJKazRteEtSZmdZckJ1RlFHYkJ6NVM4RVp5Y096S2tuVGNFNGduY01aeXYza243XzlWZU1RdFFjckdPN1pXbk5EamIyZVBTeFpIU1ZIcHZxX1kwd2VKV2dlWXFxZFRzQ094TmxTdDh0R0ZTNGozZEs3eXk1Q3liNTFMcTU3LXNhS3NUSG5fUUNGN3c?oc=5","date":"2026-02-13","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT), Tenet Healthcare (THC) and Upstream Bio, Inc. (UPB) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT), Tenet Healthcare (THC) and Upstream Bio, Inc. (","sentiment":"neutral"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-11","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-09","type":"pipeline","source":"simplywall.st","summary":"We Think Nuvectis Pharma (NASDAQ:NVCT) Can Afford To Drive Business Growth - simplywall.st","headline":"We Think Nuvectis Pharma (NASDAQ:NVCT) Can Afford To Drive Business Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOSEVWc0g2MFdqYlE4b19GWFNfcUtFR1JQY1psNFQzeVpFdFRtSTR3M0JxOUpIcW5NMDJTVWp4WFM4NlhRVTRZOUxfNVdhbjJZQkMyNDlWVk5laGowRWNvelc1NVNDVnJvX2ZTWmZ2cWtfVWpUcDZJRng5N19pQmZzSkg1VUV4T3R0NmZxM1BKWjVWNFhTRFpqNE9leFBPcF9UUlRRSTlKMVFERS16c1luZUZ4dWF2TnV6Um1LXzBDUWh0RnAtMXJ6OUZ3QmxOWUs2djhIYkxRZE1Jc1c0UHc?oc=5","date":"2025-12-17","type":"trial","source":"Quiver Quantitative","summary":"Nuvectis Pharma Initiates Phase 1b Study of NXP900 in Combination with Osimertinib for EGFRmut+ NSCLC Patients - Quiver Quantitative","headline":"Nuvectis Pharma Initiates Phase 1b Study of NXP900 in Combination with Osimertinib for EGFRmut+ NSCLC Patients","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-05","type":"earnings","source":"simplywall.st","summary":"Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; individual investors who hold 44% profited and so did insiders - simplywall.st","headline":"Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; individual investors who hold 44% profited and s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQY3NnYk5talR3WXFjZnVoX0JIYTc4Rl82RC1Wb0laZTJ1dmlUa29XVnZnVExfanhoUDZWcElCUHhEMW1tRFUwek4zbDc2a1RFWDNaTVZxZ2xXZDBUbXlJdkQwTFJ2RmVaa1lOVXM5YlNPVU5ybUZndk9JZ2JJZFJudkJnSzM4NG5hbXFFRHpHa3dmNy1hVlRrc2dSNHhvcEdGa2FkWHpYRV8zdVNFODlncUZNbVZUdnU5bEtqNw?oc=5","date":"2025-11-06","type":"deal","source":"Investing.com","summary":"Nuvectis Pharma director Sanchez buys $75k in NVCT stock - Investing.com","headline":"Nuvectis Pharma director Sanchez buys $75k in NVCT stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPLTUyR0M2bElnQmJlQXpQbm1zUWNMLXY2VWJrWWNjbXh6VW5qenJOb3R3ZGJobHZpREJ4SmYzaWtwd2JxQzVmUkNxdS1fZVR3TlRBcHhWRkZUeHVUMnFjMDlrOW4zVHBMbGFVb25CY0FaVGhVem9EOVdDVGp0MU1RNl8tQmhRdw?oc=5","date":"2025-11-04","type":"earnings","source":"Yahoo Finance","summary":"Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights - Yahoo Finance","headline":"Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights","sentiment":"neutral"},{"date":"2025-11-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-04","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[{"drugName":"NV-513","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US"}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bayer","Merck & Co.","Pfizer"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":18153000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-26442000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":31709000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}